After yesterday's volume surge, NYSE biopharma profile (ATNM) needs to be back on your watch-list today.

SmallCapFirm

Thursday Update For Your NYSE American Biopharma Profile (ATNM)

ATNM Analyst Consensus Price Target Of $67.50

October 22nd

SCF Readers,

After yesterday's volume surge, NYSE biopharma profile (ATNM) needs to be back on your watch-list today.

With the release of major news during pre-market, ATNM trended green all day and made a $1.00+ push from an open of $11.17 to a high of $12.27.

In case you missed it yesterday, make sure to read it here: Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy

Barchart is also reporting ATNM to now be a "72% BUY" based on overall technical indicators. That is a huge change from last month's "24% BUY" recommendation.

Between bullish technicals, a chart on the rise, and game-changing news, ATNM may not see its recent 2-month long vertical move slow down any time soon.

In case you haven't done so yet, read my initial report on ATNM below and get it on your radar.

-----

This morning, there is only one profile to have on your radar as several potential catalysts could be signaling an upcoming breakout for this NYSE American stock.

Pull up new biopharma idea:

Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation.

ATNM And The Significant Unmet Medical Need

Meeting an unmet medical need can be the Holy Grail for pharmaceutical companies.

Look at Actinium Pharmaceuticals for example.

At the moment, they are working towards achieving the treatment for Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML).

Unfortunately, standard therapies for R/R acute myeloid leukemia just aren’t enough.

Many patients either do not achieve complete response (CR) or relapse after CR, according to the National Center for Biotechnology Information. And although 70-80% of patients achieve CR, many patients are refractory to, or relapse, following treatment.

Plus, there is a “lack of a uniform treatment strategy for this group, with the exception of allogeneic hematopoietic cell transplantation (HCT) as the only potentially curative treatment option for patients achieving a second complete remission.

ATNM May Hold The Key To This Unmet Need

... especially after it reported a remission rate of 86% with 71% of patients achieving negative minimal residual disease status with the second dose of Actimab-A CLAG-M Combination.

At the moment, all patients in the third dosing cohort, which was scheduled as the final cohort of the planned Phase 1 dose escalation trial, completed treatment with a 0.75 uCi/kg dose of Actimab-A followed by CLAG-M and have already cleared their initial safety evaluation.

Results are expected by the end of the year.

If results are as impressive as the second dose, it could be game-changing.

Not only for the company, but also for a patient population with a current five-year survival rate of 10%, according to Blood.

Better, the remission rates of the Actinium Pharmaceuticals study are far more impressive when compared to other therapies that have been approved for treatment.

As reported by Targeted Oncology, as compared to Actinium Pharmaceuticals’ overall response rate of 86%, others aren’t even in the same ballpark.

  • 68% with gilteritinib (Xospata),
  • 64% with venetoclax (Venclexta) plus hypomethylating agents,
  • 40% with enasidenib (Idhifa),
  • 19% with venetoclax alone, and
  • 17% with azacytidine (Vidaza) alone

-----

Huge Potential Catalysts - Major Price Targets For ATNM

These targets paint the picture of a potentially extremely undervalued profile:

image

Source - MarketBeat

MarketBeat is also reporting that ATNM has a consensus price target of $67.50.

From Tuesday's closing valuation of $10.95, that gives ATNM potential upside of approximately 516%.

I'm not saying that ATNM is going to run over 500% today, but there are several analysts pointing to significant potential upside for this biopharma idea.

On top of that, Actinium Pharmaceuticals has an analyst consensus of "Strong Buy."

Key Catalysts: Red Hot Chart + Low Float + Bullish Technicals

image

As you can see in the chart above, ATNM has proven to be a short-term wrecking back on multiple occasions over the past 6 months.

From a September 4th low of $6.84 to a high this week of $12.36, ATNM has been on the move.

In a month and a half, ATNM climbed roughly 80%.

How is this possible? For one, ATNM has a low float.

According to Yahoo Finance, ATNM has a 12.34Mn shares in its float.

When a profile has that few shares available, volatility can be in the cards. Volatility can provide the potential for sharp vertical moves in the short-term.

It gets even better as ATNM is flashing strong, bullish technical indicators.

Barchart is reporting these triggered technicals as of close Tuesday:

Short Term Indicators

  • 20 Day Moving Average
  • 20 - 50 Day MACD Oscillator
  • 20 - 200 Day MACD Oscillator

Medium Term Indicators

  • 50 Day Moving Average
  • 50 - 150 Day MACD Oscillator
  • 50 - 200 Day MACD Oscillator

Long Term Indicators

  • 100 Day Moving Average
  • 150 Day Moving Average
  • 200 Day Moving Average
  • 100 - 200 Day MACD Oscillator

Additionally triggered is Barchart's composite "TrendSpotter" indicator.

-----

Last Week's Press Release - Another ATNM Potential Catalyst?

Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform

NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the launch of its new research and development lab facility in New York City. This new research facility expands Actinium's internal R&D capabilities and will be focused on developing novel Antibody Radiation Conjugate (ARC) candidates, ARC therapeutic combination strategies, and supporting AWE platform research collaborations. Actinium's R&D efforts will employ a multidisciplinary approach leveraging its team's expertise and experience in cancer cell biology, radiochemistry, radiation sciences, immunology and oncology drug development. The proprietary AWE technology platform, protected by over one hundred and twenty-five patents, is the foundation for Actinium's R&D and exploits multiple different radioisotope payloads including the potent alpha-emitter, Actinium-225.

This new research facility will function under the guidance of Dr. Dale Ludwig, Ph.D. the Company's Chief Scientific & Technology Officer, who has over twenty-five years of oncology discovery research and development experience, including supporting the development and launch of Erbitux®, CyramzaTM, Portrazza®, and LartruvoTM as well as the clinical advancement of at least 10 additional therapeutic antibodies and Antibody Drug Conjugates while at Eli Lilly and, previously, ImClone Systems Inc. The research facility will be managed and staffed by Ph.D. level scientists who will contribute their respective expertise in areas of drug discovery, radiation chemistry, and translational research to advance novel ARC programs and investigations into combination therapeutic strategies.

"Our new research facility will allow us to significantly accelerate our preclinical and clinical development of novel ARC programs and investigate mechanistic ARC therapeutic combinations, which utilize our expertise in radioimmunobiology, our AWE Technology Platform capabilities, and know-how," said Dale Ludwig. "The establishment of an internal research facility was a priority for Actinium's long-term strategy, as we look to deliver on our pipeline development activities, as well as expand our portfolio of promising product candidates through partnerships and collaborations. Furthermore, in both preclinical and clinical studies, we have shown mechanistic synergies when our ARCs are combined with novel and approved therapeutic agents in treating cancer. The addition of this R&D facility will enable more rapid investigation of novel mechanistic drug combinations that can be effectively translated into clinical testing."

Over the last eighteen months, Actinium has advanced its research and discovery activities in three key areas —the development of next generation ARCs, therapeutic combinations with ARCs, and improved targeted conditioning treatments for adoptive cell therapies such as CAR-T. As presented at the 2018 AACR Annual Meeting, cell death improved as much as thirty-fold and cell death occurred in treatment resistant cell lines when daratumumab, an anti-CD38 directed antibody approved for the treatment of multiple myeloma (MM), was labeled with Ac-225 using Actinium's AWE Technology Platform. The power and potency of Actinium's AWE Technology Platform is also demonstrated in an ongoing Actimab-A combination study with CLAG-M in difficult to treat R/R AML patients. Patients treated with a sub-therapeutic dose of Actimab-A combined with CLAG-M had improved response rates by over 60% versus CLAG-M treatment alone. In September, preclinical data supporting Iomab-ACT as a viable and effective method for achieving targeted lymphodepletion prior to an adoptive cell therapy such as CAR-T was published in the journal Oncotarget (www.oncotarget.com/archive/v11/i39/). Leveraging the new laboratory facility, Actinium intends to further its research activities in these areas which will aid in developing next generation targeted conditioning agents and exploring therapeutic combinations with ARCs and of proven oncology and immunooncology agents.

The Company intends to focus on generating novel ARCs, building on its existing intellectual property, evaluating assets for in-licensing to complement existing clinical pipeline, as well as securing collaborations and partnerships with other biopharmaceutical companies. By adding research and development capabilities to its clinical development and clinical supply chain capabilities, Actinium will be positioned to enable the rapid translation of radioimmunotherapies into the clinic. The Company's AWE platform intellectual property covers various methods of use for ARCs in multiple diseases, including indication, dose and scheduling, radionuclide warhead, and therapeutic combinations. Actinium's AWE technology patent portfolio includes 29 patent families comprised of over 130 issued or pending global patent applications, of which 10 are issued and 31 pending in the United States.

Sandesh Seth, Chairman and Chief Executive Officer of Actinium, said, "The opening of our R&D facility is an important milestone that will support both internal and collaborative efforts at advancing the field of ARCs. Our growing and highly talented R&D team is focused on harnessing the power of our AWE Technology Platform to enhance our clinical pipeline and drive current and additional collaborations. Having these capabilities in house will allow us to more efficiently execute on our multi-disciplinary research efforts and continue to innovate and extend our leadership position in the growing field of ARCs."

-----

Recap: Top 5 Potential Catalysts For ATNM

1. ATNM working towards achieving the treatment for Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

2. Huge price targets and "Strong Buy" recommendations

3. Red hot chart and bullish technicals in the short, medium, and long terms

4. ATNM's low float under 13Mn shares

5. Last week's news about a new research facility.

-----

Coverage is officially initiated on ATNM.

image

If there are any updates today, I'll get them out to you quickly.

Sincerely,

Axel Adams

Editor, SCF


Source 1

Source 2

Source 3

Source 4

Source 5


(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)​

Disclosure: Make sure to always do your own research and due diligence on any day and swing trade profile I bring to your attention. I am not a license d finan.cial advise r. All potential percentage gains are based on from the low to the high of day. SmallCapFirm's full disclosure is to be read and fully understood before using SmallCapFirm's website, or joining SmallCapFirm's email or text list. By viewing SmallCapFirm's website and/or reading SmallCapFirm's email or text newsletter you are agreeing to SmallCapFirm's full disclosure which can be read at: smallcapfirm.com/disclosure Stock Wire News (stock wire news . com) is owned by Stock News Wire LLC, a limited liability company. An owner of Stock News Wire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierce investor . com (“FI”), an interest in the limited liability company that owns and operates stock street wire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, Stock Wire News, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SmallCapFirm and StockNewsWire, LLC, SmallCapFirm was hired for a one day period on 1/13/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid five thousand USD via bank wire transfer. We own zero shares of (ATNM). An owner of StockNewsWire, LLC owns an interest in SmallCapFirm. Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews was hired for a one day period on 1/13/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (ATNM). An owner of StockNewsWire, LLC owns an interest in SmallCapFirm. Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews was hired for a one day period on 1/28/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid ten thousand USD via bank wire transfer. We own zero shares of (ATNM). An owner of StockNewsWire, LLC owns an interest in SmallCapFirm. Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews was hired for a one day period on 3/5/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (ATNM). Pursuant to an agreement between SmallCapFirm and StockNewsWire, LLC, SmallCapFirm was hired for a period beginning on 10/21/20 and ending on 10/22/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid five thousand USD via bank wire transfer. We own zero shares of (ATNM). To date, we have been compensated a total of ten thousand USD via bank wire transfer to disseminate information about (ATNM). An owner of StockNewsWire, LLC owns an interest in SmallCapFirm. Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews was hired for a period beginning on 10/21/20 and ending on 10/22/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (ATNM). To date, we have been compensated a total of sixty-five thousand USD via bank wire transfer to disseminate information about (ATNM).